Medivir's Simeprevir Aces Three Phase III HCV Trials
By Cormac Sheridan
Thursday, December 20, 2012
Top-line data from three Phase III trials of simeprevir (TMC435) in patients with hepatitis C virus (HCV) genotype 1 infection appear to confirm what Medivir AB has always maintained that it has a potentially best-in-class protease inhibitor on its hands.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.